Bernard Staumont

Dr. Bernard Staumont


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Open access
Francesco PapparlardoFrancesco Papparlardo
Francesco Papparlardo
JWJohn Wilkinson
John Wilkinson
FBFrancois Busquet
Francois Busquet
ABAntoine Bril
Antoine Bril
MPMark Palmer
Mark Palmer
Marco VicecontiMarco Viceconti
Marco Viceconti
In Silico Trials methodologies will play a growing and fundamental role in the development and de-risking of new medical devices in the future. While the regulatory pathway for Digital Patient and Personal Health Forecasting solutions is clear, it is more complex for In Silico Trials solutions, and therefore deserves a deeper analysis. In this position paper, we investigate the current state of the art towards the regulatory system for in silico trials applied to medical devices while exploring the European regulatory system toward this topic. We suggest that the European regulatory system should start a process of innovation: in principle to limit distorted quality by different internal processes within notified bodies, hence avoiding that the more innovative and competitive companies focus their attention on the needs of other large markets, like the USA, where the use of such radical innovations is already rapidly developing.

1 January 2025 in ALTEX
Verified
Journal Article
Open access
PDF file
BSBernard Staumont
Bernard Staumont
LLLuiz Ladeira
Luiz Ladeira
AGAlessio Gamba
Alessio Gamba
HHHarm J. Heusinkveld
Harm J. Heusinkveld
APAldert Piersma
Aldert Piersma
LGLiesbet Geris
Liesbet Geris
Chemical safety assessment still heavily relies on animal testing, presenting ethical dilemmas and limited human predictive value. New approach methodologies (NAMs), including in vitro and in silico techniques, offer alternative solutions. In silico toxicology has made progress in predicting chemical effects but frequently lacks biological mechanistic foundations. Recent developments focus on mechanistic understanding of adverse effects inflicted by chemicals, as embedded in (quantitative) adverse outcome pathways (AOPs). However, there is a demand for more detailed mechanistic insights at the gene and cell levels, encompassing both pathology and physiology. Drawing inspiration from the Disease Maps Project, this paper introduces Physiological Maps (PMs) as comprehensive graphical representations of biochemical processes related to specific organ functions. PMs are standardized using Systems Biology Graphical Notation and controlled vocabularies and annotations. Curation guidelines have been developed to ensure reproducibility and usability. This paper presents the methodology used to build PMs, emphasizing the essential collaboration between domain experts and curators. PMs offer user-friendly, standardized visualization for data analysis and educational purposes. Enabling a better understanding of (patho)physiology, they also complement and support the development of AOPs by providing detailed mechanistic information at the gene and cell level. Furthermore, PMs contribute to developing in vitro test batteries and to building (dynamic) in silico models aiming to predict the toxicity of chemicals. Collaborative efforts between the toxicology and systems biology communities are crucial for creating standardized and comprehensive PMs, supporting and accelerating the development of human-relevant NAMs for next-generation risk assessment. Plain language summaryAssessing the safety of chemicals still relies heavily on animal testing, which raises ethical concerns and has limited relevance to humans. New approach methodologies (NAMs), such as in silico (computer-based) models and in vitro (laboratory-based) experiments, offer promising alternatives. However, the current NAMs often lack a detailed understanding of biological mechanisms. This paper introduces Physiological Maps (PMs), in silico tools that visually represent biological processes and interactions within specific organs and cells. PMs use standardized formats and annotations, making them easy to share and understand. By providing insights into human biology, PMs complement and enhance NAMs, including adverse outcome pathways (AOPs), in vitro experiments and in silico models, aiming to improve predictions of chemical toxicity. This approach fosters collaboration between the toxicology and systems biology communities in order to advance human-relevant risk assessment methods.

7 July 2025 in Frontiers in Toxicology
Verified
Journal Article
Open access
PDF file
LLLuiz Ladeira
Luiz Ladeira
AVAnouk Verhoeven
Anouk Verhoeven
JEJonas van Ertvelde
Jonas van Ertvelde
JJJian Jiang
Jian Jiang
AGAlessio Gamba
Alessio Gamba
BSBernard Staumont
Bernard Staumont
Aims: In silico methods provide a resourceful toolbox for new approach methodologies (NAMs). They can revolutionize chemical safety assessment by offering more efficient and human-relevant alternatives to traditional animal testing. In this study, we introduce two Liver Physiological Maps (PMs); comprehensive and machine-readable graphical representations of the intricate mechanisms governing two major liver functions.Methods: Two PMs were developed through manual literature curation, integrating data from established pathway resources and domain expert knowledge. Cell-type specificity was validated using Human Protein Atlas datasets. An interactive version is available online for exploration. Cross-comparison analysis with existing Adverse Outcome Pathway (AOP) networks was performed to benchmark physiological coverage and identify knowledge gaps.Results: The LiverLipidPM focuses on liver lipid metabolism, detailing pathways involved in fatty acid synthesis, triglycerides, cholesterol metabolism, and lipid catabolism in hepatocytes. And the LiverBilePM represents bile acid biosynthesis and secretion processes, detailing biosynthesis, transport, and secretion processes between hepatocytes and cholangiocytes. Both maps integrate metabolism with signaling pathways and regulatory networks. The interactive maps enable visualization of molecular pathways, linkage to external ontologies, and overlay of experimental data. Comparative analysis revealed unique mechanisms to each map and overlaps with existing AOP networks. Chemical-target queries identified new potential targets in both PMs, which might represent new molecular initiating events for AOP network extension.Conclusion: The developed liver PMs serve as valuable resources for hepatology research, with a special focus on hepatotoxicity, supporting the refinement of AOP networks and the development of human-oriented in vitro test batteries for chemical toxicity assessment. These maps provide a foundation for creating computational models and mode-of-action ontologies while potentially extending their utility to systems biology and drug discovery applications.

6 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
BSBernard Staumont
Bernard Staumont
MJMajeed Jamakhani
Majeed Jamakhani
CCChrisostome Costa
Chrisostome Costa
FVFabian Vandermeers
Fabian Vandermeers
SSSathya Neelature Sriramareddy
Sathya Neelature Sriramareddy
LWLuc Willems
Luc Willems
Background: There is no standard chemotherapy for refractory or relapsing malignant pleural mesothelioma (MPM). Our previous reports nevertheless indicated that a combination of an anthracycline (doxorubicin) and a lysine deacetylase inhibitor (valproic acid, VPA) synergize to induce the apoptosis of MPM cells and reduce tumor growth in mouse models. A Phase I/II clinical trial indicated that this regimen is a promising therapeutic option for a proportion of MPM patients. Methods: The transcriptomes of mesothelioma cells were compared after Illumina HiSeq 4000 sequencing. The expression of differentially expressed genes was inhibited by RNA interference. Apoptosis was determined by cell cycle analysis and Annexin V/7-AAD labeling. Protein expression was assessed by immunoblotting. Preclinical efficacy was evaluated in BALB/c and NOD-SCID mice. Results: To understand the mechanisms involved in chemoresistance, the transcriptomes of two MPM cell lines displaying different responses to VPA-doxorubicin were compared. Among the differentially expressed genes, transforming growth factor alpha (TGFα) was associated with resistance to this regimen. The silencing of TGFα by RNA interference correlated with a significant increase in apoptosis, whereas the overexpression of TGFα desensitized MPM cells to the apoptosis induced by VPA and doxorubicin. The multi-targeted inhibition of histone deacetylase (HDAC), HER2 and TGFα receptor (epidermal growth factor receptor/EGFR) improved treatment efficacy in vitro and reduced tumor growth in two MPM mouse models. Finally, TGFα expression but not EGFR correlated with patient survival. Conclusions: Our data show that TGFα but not its receptor EGFR is a key factor in resistance to MPM chemotherapy. This observation may contribute to casting light on the promising but still controversial role of EGFR signaling in MPM therapy.

18 May 2026 in Frontiers in Toxicology
Verified
Journal Article
Open access
LLLuiz Ladeira
Luiz Ladeira
DBDevon A. Barnes
Devon A. Barnes
RMRosalinde Masereeuw
Rosalinde Masereeuw
LGLiesbet Geris
Liesbet Geris
BSBernard Staumont
Bernard Staumont
Introduction: Chemical-induced heart toxicity remains a major challenge in drug development and environmental safety, largely because current testing often relies on narrow, late-stage endpoints that miss the complex biological progression of the toxicities. To address this, we developed a comprehensive Adverse Outcome Pathway (AOP) network that maps how early (bio) chemical triggers evolve into organ-level dysfunction. Methods: By integrating data from the OECD AOP-Wiki, we constructed a unified network of 64 biological events and 94 documented relationships that identifies the critical biological “crossroads” where different toxic chemicals converge to cause heart damage. Results/discussion: Our analysis reveals a compact core of central biological events, such as oxidative stress and mitochondrial dysfunction, which act as the primary drivers of cardiac injury. This network approach moves beyond single, linear pathways to show how systemic factors, including interactions with other organs like the kidneys, contribute to cardiotoxicity. To translate these findings into a practical resource for the broader scientific community, we developed a methods catalogue that links these biological events to specific laboratory assays. To ensure this work is accessible and actionable, we hosted the network on an interactive, FAIRaligned web platform. By providing a clear scaffold for understanding heart safety, this resource enables the design of more human-relevant, animal-free testing strategies and helps prioritise the most impactful biomarkers for future safety assessments.

23 February 2024
Verified
Book Chapter
Open access
PDF file
Marco VicecontiMarco Viceconti
Marco Viceconti
LGLiesbet Geris
Liesbet Geris
LELuca Emili
Luca Emili
ALAxel Loewe
Axel Loewe
BSBernard Staumont
Bernard Staumont
RLRaphaëlle Lesage
Raphaëlle Lesage
'Introduction' published in 'Toward Good Simulation Practice'